Why Adaptimmune Therapeutics Stock Is Crashing Today

Shares of the clinical-stage cell therapy company Adaptimmune Therapeutics (NASDAQ: ADAP) were down by 9.1% as of 2:37 p.m. ET on Wednesday. Earlier today, the biotech's shares were down by an unsightly 12.5% at their low point.

Investors appear to be throwing in the towel on Adaptimmune stock today for three reasons:

Image source: Getty Images.

Continue reading

Source Fool.com